People with mild cognitive impairment due to Alzheimer's can now compare biweekly clinic IV Leqembi with weekly at-home autoinjections. Eisai and Biogen report FDA approval on July 13, 2026, for 500-mg weekly at-home initiation as two 250-mg autoinjections the FDA approval notice.
Leqembi (lecanemab) is a prescription treatment that targets amyloid in early Alzheimer's. Training is the bridge between the two routes. It teaches the patient and a caregiver how to give the two shots correctly, what schedule to follow, and when to call the clinic.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is the at-home regimen for?
- How do the routes differ in time and place?
- What does training require?
- What support do you need at home?
- How to discuss the choice with your clinician?
Who is the at-home regimen for?
The companies state the regimen is for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease, a group called early Alzheimer's the FDA approval announcement. They also state confirmed amyloid pathology is required for IV Leqembi eligibility.
Mild cognitive impairment means early changes in memory or thinking that do not prevent daily tasks. Mild dementia means those changes have started to affect daily tasks. A clinician confirms the cause and stage before treatment starts.
How do the routes differ in time and place?
Medscape reports each maintenance injection takes about 15 seconds, compared with about one-hour biweekly IV infusions at 10 mg/kg, eliminating dozens of infusion-center visits over treatment Medscape's home-treatment analysis. The IV route happens in an infusion center on a biweekly schedule. The at-home route happens on a weekly schedule after training.
- Clinic IV: travel, check-in, hour-long infusion, observation, return home.
- Home shots: two autoinjections in sequence, brief time, no infusion chair.
- Calendar load: weekly home tasks replace fewer but longer clinic days.
What does training require?
Medscape notes at-home use still requires clinician oversight, caregiver and patient injection training, and MRI monitoring for amyloid-related imaging abnormalities, or ARIA the same home-treatment analysis. ARIA means brain swelling or bleeding signals seen on MRI.
It is not a simple take-at-home drug. Training usually covers the full weekly sequence in order. Ask the nurse to watch a full practice run.
- Give the two shots in the taught order without skipping.
- Follow the weekly schedule and record each dose date.
- Store and handle autoinjectors exactly as instructed.
- Call promptly for headache, confusion, dizziness, vision change, or falls.
What support do you need at home?
A reliable second person matters more than steady hands. The caregiver learns the steps, tracks dates, watches for new symptoms, and drives to MRI visits. People living alone should name a backup helper before starting.
Comfort with needles, vision, grip strength, and home routine also shape the choice. Some people prefer a clinic team to manage each dose. Others prefer brief home tasks over travel and waiting rooms.
How to discuss the choice with your clinician?
Bring a list of current drugs, travel limits, work schedules, and caregiver availability. Ask who provides training, how many practice sessions are offered, and what happens if a weekly dose is missed. Ask where MRIs will occur and how results reach you.
Use one visit to compare burdens side by side. Note infusion travel time, home task time, MRI dates, and symptom reporting steps. Bring your caregiver to the training visit and leave with a written after-hours contact.
You Might Also Like
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: How People With Mild Cognitive Impairment Can Compare Treatment Routes
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- Common Barriers to Music Practice for Dementia Prevention With Mild Cognitive Impairment
